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The DBCCR1 gene at chromosome 9q33 has been identified as a candidate tumour suppressor, which is frequently targeted by
promoter hypermethylation in bladder cancer. Here, we studied the possible involvement of DBCCR1 in the development of oral
squamous cell carcinoma. DNA from 34 tumours was examined for loss of heterozygosity (LOH) at three markers surrounding
DBCCR1 and for hypermethylation of the DBCCR1 promoter, using methylation-specific PCR and methylation-specific melting-curve
analysis. LOH was found in 10 of 31 cases (32%), and DBCCR1 hypermethylation was present in 15 of 34 cases (44%).
Hypermethylation of DBCCR1 was also present in three of seven epithelial tissues adjacent to the tumours, including two hyperplastic
and one histologically normal epithelia. Furthermore, of four oral leukoplakias with dysplasia, one showed LOH at 9q33 and two
showed DBCCR1 hypermethylation. These data suggest that LOH at 9q33 and hypermethylation of the DBCCR1 promoter are
frequent and possibly early events in oral malignant development.
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Oral cancer comprises about 3% of all newly diagnosed cancer
cases in the Western countries. Despite advances in therapy, the 5-
year survival rate after diagnosis is still poor and remains B50%
(Landis et al, 1999; Silverman, 2001). Clinically, oral carcinomas
often develop in a two-step process. The first step is characterised
by the appearance of potentially malignant lesions such as
leukoplakias and erythroplakias, and the second step is char-
acterised by the development of carcinomas. However, clinical and
histopathological features are insufficient measures for predicting
the prognosis of potentially malignant lesions (Warnakulasuriya,
2000, 2001). Furthermore, a recent study indicated that clinically
and histologically normal mucosa adjacent to tumours may
harbour patches of genetically altered cells (Braakhuis et al,
2003). It is, therefore, important to find molecular markers for
identifying the minor fraction of oral lesions that will develop into
carcinoma.
Loss of heterozygosity (LOH) at multiple chromosome regions
and genetic and epigenetic alterations of several proto-oncogenes
and tumour suppressor genes have been demonstrated in oral
carcinomas, including alterations of the TP53, p16, p15, MGMT, E-
cadherin genes and RAS (Califano et al, 1996; Partridge et al, 1999;
Williams, 2000; Ogi et al, 2002; Viswanathan et al, 2003). In
addition, our previous study showed that hypermethylation of the
ABO gene promoter was associated with loss of expression of A/B
antigen in approximately one-third of oral squamous cell
carcinomas (Gao et al, 2004). LOH at 9q34, in which the ABO
gene is located, was also a frequent event in these tumours.
However, a number of tumours from AO and BO heterozygotes
showed deletion of the O allele, which does not encode a functional
glycosyltransferase, suggesting the existence of an additional
tumour suppressor gene on chromosome 9q. The DBCCR1 (deleted
in bladder cancer chromosomal region candidate 1) gene at
chromosome 9q33 was identified as a putative tumour suppressor
gene that is frequently targeted by hypermethylation in transitional
cell carcinomas of the bladder (Habuchi et al, 1997, 1998, 2001;
Nishiyama et al, 1999). There are, at present, no reports of
DBCCR1 alterations in other cancers. The aim of this study was to
examine for LOH at the 9q33 region and determine the
methylation status of DBCCR1 in oral squamous cell carcinomas
and potentially malignant oral lesions.
MATERIALS AND METHODS
Sample preparation
Surgical specimens of oral lesions were obtained from School of
Dentistry, National Yang-Ming University, Taipei, and Odense
University Hospital, Denmark. The median age of the patients was
60 years (range 35–89 years); there were six women and 32 men.
The materials included unfixed frozen tissues from 34 patients
with oral squamous cell carcinoma and four patients with poten-
tially malignant lesions (leukoplakia with epithelial dysplasia). A
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slaser microdissection system (PALM) was used to separate tumour
cells or leukoplakia epithelium from normal connective tissue. In
seven cases, tumour-adjacent epithelium was isolated as well. DNA
was extracted by routine procedures using the DNeasy Kit
(Qiagen). Informed consent and approval by the Ethics Committee
were obtained according to Danish legislation.
LOH analysis
DNA from tumour or leukoplakia lesions and matched normal
tissues was screened for LOH at the 9q33 region using the three
microsatellite markers, D9S195, D9S1872 (http://www.gdb. org)
and 9-11407. The latter marker was designed by one of us (HE) and
is located B300kb upstream of exon 1 of the DBCCR1 gene,
according to GenBank accession no. AY438564. The primer
sequences of 9-11407 were 50-CAACAAAGTCAATCCCAGCA-30
and 50-GGTTCACTAAGAGCACAATTGTTTA-30. PCR was per-
formed using a
33P end-labelled primer, and the amplified
fragments were separated by electrophoresis in a 6% denaturing
polyacrylamide gel, as described elsewhere (Gao et al, 2004). LOH
was determined as at least a 50% reduction in the relative intensity
of one allele compared with the normal control. Control samples
were included during all procedures.
Methylation analysis
Genomic DNA was treated with sodium bisulphite as described
previously (Clark et al, 1994). For methylation-specific PCR (MS-
PCR) analysis of the DBCCR1 promoter (GenBank accession no.
AF027734), the primers for the unmethylated reaction were 50-
TTTATGGTTGTAAATTGATTTGGTGTGT-30 and 50-CAACTCA-
CATTCCAAACACAACACA-30, which amplify a 269-bp product
(positions 15–283), and the primers for the methylated reaction
were 50-TTGTAAATTGATTTGGCGCGC-30 and 50-TTCCGAACAC-
GACGCGAAA-30, which amplify a 253-bp product (positions 22–
274). PCR was carried out using the HotStarTaq Kit (Qiagen); the
annealing temperatures for the unmethylated and methylated
reactions were 60 and 621C, respectively. Primer sequences and
reaction conditions for MS-PCR analysis of the ABO gene
promoter were as described (Kominato et al, 1999; Gao et al,
2004). The PCR products were resolved on 2% agarose gels. DNA
treated with SssI methyltransferase (New England Biolabs) served
as the methylated control.
For methylation-specific melting-curve analysis (MS-MCA) of
DBCCR1, the primers were 50-GGGAGGTAGAGGGAGTAGTGAT-
30 and 50-AAAATACCTAACTCCTAACAACCTAAC-30, which am-
plify a 117-bp product (positions 127–243). PCR and subsequent
MCA were carried out as previously described (Worm et al, 2001)
using the LightCycler (Roche) and the FastStart DNA Master SYBR
Green I Kit (Roche). Reactions were started by initial denaturation
at 951C for 10min, followed by cycling at 951C for 10s, a transition
from 72 to 661C at 0.51Ccycle
 1 for 10s and 721C for 20s. Melting-
curve analysis was performed immediately after amplification by
measuring the fluorescence of SYBR Green I during a linear
temperature transition from 70 to 951C at 0.051Cs
 1. Fluorescence
data were converted into melting peaks by the LightCycler software
Table 1 Hypermethylation of DBCCR1 and LOH at 9q33 in oral
squamous cell carcinomas and leukoplakias with dysplasia
Hypermethylation LOH
Case # Sex Age DBCCR1 ABO
D9S
1872
D9S
195 9-11407
Carcinomas
1 CT5 M 54 +     +
2 CT6 M 56         
3 CT7 M 60 +      
4 CT8 M 62    +   
5 CT10 M 57   +N A N A N A
6 CT11 M 57   +     
7 CT12 M 50         
8 CT14 M 50 +      
9 CT15 M 53         
10 CT16 M 37 +      
11 CT17 M 57         
12 CT18 M 65 + +   +  
13 CT19 M 58         
14 CT20 M 54         
15 CT21 M 71         
16 CT22 M 65         
17 CT23 M 35 +* +*     
18 CTGx F 57 + + + + +
19 30365 M 66 +   NA NA NA
20 19395 M 61 +     +
21 25941 M 65         
22 15374 M 69   +     
23 18034 M 76    NA NA NA
24 31572T1 F 55 + +   +  
31572T2 + + + + +
25 33379 M 84         
26 28753 F 52 +    ++
27 19274 M 61      +  
28 2132 M 58 +* +     
29 1592 F 71 +      
30 17093 M 60    ++ +
31 29627 M 61         
32 21394 M 69 + +     
33 27088 F 89 +* +*    +
34 33103 M 69   +     
Leukoplakias with dysplasia
35 6042 F 60         
36 24710 M 54    +   
37 24722 M 53 +      
38 16050 M 51 +      
NA¼no available information; T1¼well-differentiated tumour cells adjacent to
normal epithelium. T2¼poor-differentiated tumour cells far away from normal
epithelium. *Hypermethylation was found in both normal epithelia and tumour cells.
Figure 1 LOH analysis of 9q33 in oral squamous cell carcinomas. T,
tumour; N, normal tissue; T1, well-differentied tumour cells adjacent to
normal epithelium; T2, poor-differentied tumour cells far away from normal
epithelium. Arrows indicate LOH.
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s(Ver.3.39) by plotting the negative derivative of fluorescence over
temperature vs temperature ( dF/dTv sT ).
Statistical analysis
Correlation analyses were performed using Fisher’s exact prob-
ability test.
RESULTS
LOH analysis of chromosome 9q33
LOH analysis of the 9q33 region using three microsatellite markers
showed allelic loss in 10 of 31 (32%) informative cases of oral
squamous cell carcinoma (Table 1; see Figure 1 for examples).
Among these, four showed LOH at D9S1872, six at D9S195, and
seven at 9-11407. Notably, three cases showed LOH at 9-11407
located B300kb upstream of DBCCR1, but retention of D9S195
located in intron 1 of DBCCR1. In one case, in which DNA was
isolated from both well- and poor-differentiated tumour cells from
the same tumour, LOH at D9S195 was found in both populations,
but only the poor-differentiated tumour cells showed LOH at 9-
11407 and D9S1872 (Figure 1). LOH at D9S1872 was also found in
one of four leukoplakias with dysplasia. No LOH was found in
epithelial tissues adjacent to the tumours.
Methylation analysis
Hypermethylation of the DBCCR1 gene promoter was present in 15
out of 34 (44%) oral squamous cell carcinomas, as determined by
MS-PCR analysis (Table 1; see Figure 2 for examples). In three out
of seven cases, DBCCR1 hypermethylation was also found in
tumour-adjacent tissues, including two hyperplastic and one
histologically normal epithelia. To further characterise DBCCR1
methylation patterns in oral carcinomas and to exclude possible
false-positive MS-PCR results, all samples showing a positive
signal for methylated DBCCR1 alleles using MS-PCR were also
examined using MS-MCA (Figure 2). Aberrant methylation was
confirmed in all cases. However, in one case (#31572), well- and
poor-differentiated tumour cells isolated from the same lesion
showed different methylation patterns (Figure 2). Hypermethyla-
tion of the DBCCR1 gene was also found in two of four
leukoplakias with dysplasia, none of which showed LOH at 9q33
(Table 1).
Concomitant LOH at 9q33 and hypermethylation of the DBCCR1
gene were found in seven carcinomas (P¼0.057); however, this
Figure 2 Methylation analysis of the DBCCR1 gene promoter in oral squamous cell carcinomas. Left, MS-PCR. Genomic DNA was treated with sodium
bisulphfite and PCR-amplified with primer pairs specific for methylated (M) and unmethylated (U) alleles. Right, MS-MCA. Bisulphfite-treated DNA was
amplified in the presence of SYBR Green I using primers that do not discriminate between methylated and unmethylated DBCCR1 alleles. The melting
characteristics of the PCR products were determined directly in the PCR tube by continuous fluorescence monitoring during a temperature transition. SssI-
methylated DNA and genomic DNA from normal peripheral blood lymphocytes (PBL) provided positive controls for methylated and unmethylated
DBCCR1 alleles, respectively. Tu, tumour; Ep, epithelium; Cn, connective tissue; T1, well-differentiated tumour cells adjacent to normal epithelium; T2, poor-
differentiated tumour cells far away from normal epithelium.
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which is located B300kb upstream of exon 1 of the DBCCR1 gene
(Table 2). Hypermethylation of ABO was found in 11 out of 34
(32%) tumour samples and in three adjacent epithelia (Table 1)
(Gao et al, 2004), but there was no correlation between the
DBCCR1 and ABO hypermethylation events (P ¼ 0.11; Tables 1
and 2).
DISCUSSION
Substantial evidence suggests that aberrant hypermethylation of
promoter CpG islands may constitute an alternative mechanism to
intragenic mutations and deletions for inactivation of tumour
suppressor genes (Worm and Guldberg, 2002; Nephew and Huang,
2003). Hypermethylation of the DBCCR1 gene as well as LOH and
homozygous deletions at the DBCCR1 locus have been shown to be
frequent events in bladder cancer (Fujiwara et al, 2001; Habuchi
et al, 1998, 2001; Nishiyama et al, 1999). Previous studies of head
and neck carcinomas have demonstrated LOH involving the 9q32-
33 region, which covers the DBCCR1 gene (Ah-See et al, 1994). In
the present study, LOH at 9q33 was found in 32% of oral squamous
cell carcinomas, suggesting that this region contains a tumour
suppressor gene involved in oral carcinogenesis. Notably, LOH
frequently involved microsatellite marker D9S195, which is located
in intron 1 of DBCCR1 and was originally used to identify this gene
as a candidate tumour suppressor (Habuchi et al, 1997).
Methylation analysis of the DBCCR1 promoter region using two
different techniques showed aberrant hypermethylation in 44% of
the tumours. These data add DBCCR1 to the list of tumour
suppressor genes known to be targeted by promoter hypermethy-
lation in oral carcinomas, including p16, p15, E-cadherin, MGMT
and ABO (Akanuma et al, 1999; Kim et al, 2000; Yakushiji et al,
2001; Chang et al, 2002; Hasegawa et al, 2002; Viswanathan et al,
2003; Gao et al, 2004). No correlation was found between
hypermethylation of DBCCR1 at 9q33 and ABO at 9q34, suggesting
that these genes are epigenetically targeted in oral carcinogenesis
by independent and possibly specific events.
Genetic and epigenetic alterations of the DBCCR1 gene were not
restricted to oral carcinomas. LOH at 9q33 was also demonstrated
in one of four patients with severe epithelial dysplasia, and
DBCCR1 hypermethylation was present in another two of these
four cases. Aberrant hypermethylation levels were found even in
tumour-adjacent epithelia with no histopathological evidence of
malignancy, suggesting that it may represent an early event in oral
malignant development. In bladder cancer, field cancerisation has
been attributed to age-related methylation of DBCCR1 in normal
epithelium (Habuchi et al, 2001). The presence of DBCCR1
hypermethylation in oral tumour-adjacent epithelium is of great
interest and should be further investigated in order to elucidate
whether local recurrence or field cancerisation in oral cancer
patients can be explained, at least in some cases, by the existence
of a DBCCR1-hypermethylated field in histologically normal
epithelium.
In the present work, we were not able to detect any divergence
between the two groups of patients, which were of different ethic
origin and exposed to different environmental factors (betel/
tobacco and alcohol/tobacco). However, the material is too limited
to make any firm conclusions. In a new prospective study, we are
investigating whether the methylation and LOH status have a
clinical significance.
There is still little information about the possible function of the
DBCCR1 gene in carcinogenesis. Unresolved issues include the
apparent lack of DBCCR1 expression in most normal tissues and
the unclear correlation between hypermethylation and transcrip-
tional silencing of this gene (Habuchi et al, 1998), questioning the
role of DBCCR1 as a tumour suppressor in the homeostasis of
normal cells. Previous cell cycle studies suggested that DBCCR1
has growth-suppressing and antiproliferative activities mediated
via modulation of the G1 checkpoint. Overexpression of DBCCR1
caused a slower G1 transition rather than G1 arrest and did not
affect apoptosis (Nishiyama et al, 2001). Although these functional
studies and the high rate of DBCCR1 hypermethylation in oral
squamous cell carcinomas support the candidacy of DBCCR1 as a
tumour suppressor at 9q33, additional studies are required to
unravel its possible role in oral malignant development.
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